Actively Recruiting

Phase Not Applicable
Age: 18Years - 85Years
All Genders
ID06294613

A Prospective, Open-label, Single-center, Study of the ACUSURGICAL Luca System for Treatment of Vitreoretinal Diseases

Led by Acusurgical · Updated on 2025-01-30

15

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are studying the ACUSURGICAL Luca System in a prospective, open-label, single-center trial in Belgium to treat vitreoretinal diseases such as intravitreal hemorrhage and macular pucker. This study involves up to 15 participants undergoing vitreoretinal surgery, with only one eye per subject enrolled. The study focuses on evaluating the safety of this surgery system over a three-month period. Participants will undergo vitreoretinal surgery supported by the Luca System under general anesthesia. The study includes patients who are pseudophakic or aphakic, aged between 18 and 85 years, and who require vitrectomy to address specific eye conditions. The trial is monocentric and non-controlled, meaning all participants will receive the same surgical intervention without comparison groups. During the study, participants will have follow-up visits to monitor safety outcomes and assess visual function. Researchers will evaluate safety measures over three months after surgery. Participants must be able to comply with scheduled visits and have health insurance. The total participation duration is centered around surgery and post-operative monitoring within this timeframe.

CONDITIONS

Brief Title

A Prospective, Open-label, Single-center, Study of the ACUSURGICAL Luca System for Treatment of Vitreoretinal Diseases

Who Can Participate

Age: 18Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Given written Informed Consent by subject
  • Males or females aged 18 - 85 years, pseudophakic or aphakic
  • Willing and able to comply with the schedule for follow-up visits
  • Requiring vitrectomy under general anesthesia (conditions include vitreous hemorrhage treatment, diabetic retinopathy, vascular occlusion, adverse effect of anticoagulant therapy, macular pucker)
  • Best Corrected Distance Visual Acuity (BCDVA) less than 7/10
  • Deemed fit for robotic surgery per surgeons' assessment, including ability to undergo general anesthesia
  • Beneficiary of health insurance
Not Eligible

You will not qualify if you...

  • Uncontrolled systemic disease that could increase operative risk or confound the outcome (autoimmune disease, uncontrolled hypertension, lung and heart disease impairing respiratory function, or other medical conditions as deemed by Clinical Investigator)
  • Body Mass Index (BMI) over 30 kg/m8
  • Axial length less than 22 mm or greater than 26 mm per ocular biometry
  • Presence of clinically significant ocular inflammation or infection within 30 days before Preoperative Visit, such as cystoid macular edema (CME), uveitis
  • Ocular conditions that may predispose to future complications or confound visual acuity results, including profound amblyopia (less than 1/10) or strabismus
  • Ocular condition requiring additional surgical manipulation, such as membrane peeling or retinal neovascular formation
  • Already vitrectomized on the study eye
  • Presenting retinal detachment or retinal tear
  • History of ocular trauma or post-traumatic vitreous hemorrhage
  • Corneal scar preventing clear visualization of fundus
  • Uncontrolled ocular pathology or degenerative disorder such as glaucoma with visual defect or uncontrolled intraocular pressure, uveitis, optic nerve damage
  • Subjects without light perception
  • Participation in other clinical studies
  • Dependence on the Sponsor or Clinical Investigator
  • Pregnant or lactating women based on self-declaration

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Surgery and Immediate Post-operative Care

Duration - Up to 3 months

Participants undergo vitreoretinal surgery supported by the Luca System under general anesthesia followed by immediate post-operative care.

1 surgery visit and multiple post-operative follow-up visits

Trial Site Locations

Total: 1 location

1

UZ Gent

Ghent, East Flanders, Belgium, 9000

Actively Recruiting

Loading map...

Research Team

C

Charlene Braun

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Similar Trials

Nuclear Magnetic Resonance (NMR)-Based Metabolomic Character...

Vitreoretinal Disease

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here